


# Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the application:

1. (Currently amended) A compound structurally represented by Formula I,



or pharmaceutically acceptable salts thereof, wherein:

R<sup>1</sup> and R<sup>2</sup> are independently H, or -O R<sup>3</sup> N R<sup>4</sup> R<sup>5</sup>, provided that one of R<sup>1</sup> and R<sup>2</sup> is -O R<sup>3</sup> N R<sup>4</sup> R<sup>5</sup>, and provided that only one of R<sup>1</sup> and R<sup>2</sup> is ~~can be~~ -O R<sup>3</sup> N R<sup>4</sup> R<sup>5</sup>;

R<sup>3</sup> is ~~(C<sub>2</sub>-C<sub>5</sub>)~~ (C<sub>2</sub>-C<sub>5</sub>) alkylene;

R<sup>4</sup> is (C<sub>1</sub>-C<sub>4</sub>) alkyl;

R<sup>5</sup> is (C<sub>1</sub>-C<sub>4</sub>) alkyl,

wherein R<sup>4</sup> and R<sup>5</sup> taken together with the nitrogen atom to which they are attached can form a piperidinyl or pyrrolidinyl ring;

X is CH<sub>2</sub> or CO;

Y and Z are ~~-CH<sub>2</sub>-~~ -CH<sub>2</sub>- or N, provided that one of Y or Z is N, and provided that only one of Y and Z ~~can be~~ is N;

R<sup>6</sup> is hydrogen,

- (C<sub>1</sub>-C<sub>4</sub>) alkyl,

-CH<sub>2</sub> -phenyl,

-CH<sub>2</sub> (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl,

-CO<sub>2</sub>R<sup>8</sup>,

-SO<sub>2</sub>R<sup>9</sup>,

-CONH R<sup>10</sup>,

-COR<sup>11</sup>,

-CH<sub>2</sub>CH<sub>2</sub>N R<sup>12</sup> R<sup>13</sup>, or

-CH<sub>2</sub>R<sup>14</sup>;

R<sup>7</sup> is hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>) alkyl,

-CH<sub>2</sub> - phenyl,

-CH<sub>2</sub>(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl,

-CO<sub>2</sub>R<sup>8</sup>,

-SO<sub>2</sub>R<sup>9</sup>,

-CONH R<sup>10</sup>,

-COR<sup>11</sup>,

-CH<sub>2</sub>CH<sub>2</sub>N R<sup>12</sup> R<sup>13</sup>, or

-CH<sub>2</sub>R<sup>14</sup>;

Wherein;

R<sup>8</sup> is

-(C<sub>1</sub>-C<sub>4</sub>) alkyl, or

-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl;

R<sup>9</sup> is

-(C<sub>1</sub>-C<sub>4</sub>) alkyl,

-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, or

- phenyl;

R<sup>10</sup> is

-(C<sub>1</sub>-C<sub>4</sub>) alkyl, or

-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl;

R<sup>11</sup> is

-(C<sub>1</sub>-C<sub>4</sub>) alkyl,

-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl,

-CH<sub>2</sub>N R<sup>12</sup> R<sup>13</sup>, or

-(C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, wherein optionally one or more of said carbons is replaced by N, NR<sup>10</sup>, or NCO<sub>2</sub> R<sup>10</sup>;

R<sup>12</sup> is

- hydrogen, or  
- (C<sub>1</sub>-C<sub>4</sub>) alkyl;

R<sup>13</sup> is







- hydrogen,  
- (C<sub>1</sub>-C<sub>4</sub>) alkyl,  
- CO<sub>2</sub>R<sup>10</sup>, or  
- phenyl;









R<sup>14</sup> is








- (C<sub>1</sub>-C<sub>4</sub>) alkyl, or  
- (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl, wherein optionally one or more of said carbons is replaced by N, NR<sup>10</sup>, or NCO<sub>2</sub>R<sup>10</sup>.









2. (Original) The compound of claim 1, wherein R<sup>2</sup> is hydrogen and R<sup>1</sup> is -O R<sup>3</sup> N R<sup>4</sup> R<sup>5</sup>.
3. (Original) The compound of claim 2 wherein R<sup>3</sup> is -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-.
4. (Currently amended) The compound of ~~any of claims 1-3~~ 3 wherein R<sup>4</sup> and R<sup>5</sup> taken together with the nitrogen atom to which they are attached form a piperidinyl ring.
5. (Currently amended) The compound of ~~any of claims 1-4~~ 1 wherein Z is N and Y is CH<sub>2</sub>.
6. (Currently amended) The compound of ~~any of claims 1-4~~ 1 wherein Y is N and Z is CH<sub>2</sub>.
7. (Currently amended) The compound of ~~any of claims 1-6~~ 1 wherein X is CO.
8. (Currently amended) The compound of claim 1 further represented by any one of formula (Example 1) to (Example 36) selected from the group consisting of:

Example Number	Structure
1	 <chem>CC(C)(C)OC(=O)N1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
2	 <chem>[Cl-]c1ccc2c(c1)CNCC2OCCCN3CCCCC3</chem>
3	 <chem>CC(C)N(C(=O)N1CCc2ccc(OCCCN3CCCCC3)cc21)C</chem>
4	 <chem>c1ccccc1CN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
5	 <chem>C1CCCCC1CN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>



6	 <chem>CC(C)N1CCCCC1CCCOc2ccc3c(c2)CCN(C(C)C)CC3</chem>
7	 <chem>C1CCCCC1CN2CCCCC2c3ccc4c(c3)CCN(C(C)C)CC4</chem> <chem>O=C(O)C(O)=C(O)C(=O)O</chem>
8	 <chem>CN(C)CC(=O)N1CCCCC1CCCOc2ccc3c(c2)CCN(C(C)C)CC3</chem>
9	 <chem>CCN1CCCCC1CCCOc2ccc3c(c2)CCN(C(C)C)CC3</chem>
10	 <chem>c1ccccc1CN2CCCCC2c3ccc4c(c3)CCN(C(C)C)CC4</chem>
11	 <chem>C1CCCCC1CN2CCCCC2c3ccc4c(c3)CCN(C(C)C)CC4</chem>

12	
13	
14	
15	
16	
17	
18	
19	

20	
21	
22	
23	
24	
25	
26	

27	
28	 Chiral
29	 Chiral
30	 HCl HCl
31	
32	 Chiral
33	 Chiral CH CH
34	



35	
36	

- or a pharmaceutically acceptable salt or solvate thereof.
9. (Currently amended) A pharmaceutical composition which comprises a compound of ~~any of claims 1-8~~ 1 or 8 and a pharmaceutically acceptable carrier.
  10. (Cancelled)
  11. (Cancelled)
  12. (Cancelled)
  13. (Currently amended) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of Claims 1-8~~ 1 or 8.
  14. (Original) The method of Claim 13 wherein the antagonist is a pharmaceutical composition of claim 9.
  15. (Currently amended) A method for treatment or prevention of a cognitive disorder ~~or disease in which inhibition of the histamine H3 receptor has a beneficial effect~~ which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of claims 1-8~~ 1 or 8.
  16. (New) The method of Claim 15 wherein the antagonist is a pharmaceutical composition of claim 9.